Literature DB >> 11035773

Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells.

F Luhder1, C Chambers, J P Allison, C Benoist, D Mathis.   

Abstract

Engagement of the T cell costimulatory receptor CTLA-4 can potently down-regulate an immune response. For example, in a T cell receptor transgenic mouse model of autoimmune diabetes, CTLA-4 interactions keep pancreatic islet-reactive T cells in check, evidenced by the finding that mAb blockade of CTLA-4 rapidly provokes diabetes in animals that would not normally succumb until many months later. Interestingly, this effect is only observed early in the course of disease, before insulitis is stably entrenched. Here, we have exploited a highly synchronous and easily manipulable transfer system to determine precisely when CTLA-4 must be engaged to check the diabetogenicity of islet-reactive T cells. Our results indicate that CTLA-4 interactions during initial priming of the T cells in the pancreatic lymph nodes are not determinant. Rather, the critical interactions occur when the T cells secondarily reencounter their antigen in the target organ, the pancreatic islets. In addition, we made use of CTLA-4-deficient mice to bolster our interpretation that CTLA-4 engagement has a dampening rather than an enhancing influence on diabetes progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035773      PMCID: PMC17319          DOI: 10.1073/pnas.200348397

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

1.  CTLA-4-Mediated inhibition of early events of T cell proliferation.

Authors:  M C Brunner; C A Chambers; F K Chan; J Hanke; A Winoto; J P Allison
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

Review 2.  Costimulatory regulation of T cell function.

Authors:  C A Chambers; J P Allison
Journal:  Curr Opin Cell Biol       Date:  1999-04       Impact factor: 8.382

3.  The role of CTLA-4 in regulating Th2 differentiation.

Authors:  M A Oosterwegel; D A Mandelbrot; S D Boyd; R B Lorsbach; D Y Jarrett; A K Abbas; A H Sharpe
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

4.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.

Authors:  V L Perez; L Van Parijs; A Biuckians; X X Zheng; T B Strom; A K Abbas
Journal:  Immunity       Date:  1997-04       Impact factor: 31.745

5.  ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.

Authors:  A Hutloff; A M Dittrich; K C Beier; B Eljaschewitsch; R Kraft; I Anagnostopoulos; R A Kroczek
Journal:  Nature       Date:  1999-01-21       Impact factor: 49.962

6.  Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.

Authors:  B R Blazar; P A Taylor; A Panoskaltsis-Mortari; A H Sharpe; D A Vallera
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

7.  Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses.

Authors:  C A Chambers; M S Kuhns; J P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

Review 8.  CTLA-4 and T cell activation.

Authors:  M A Oosterwegel; R J Greenwald; D A Mandelbrot; R B Lorsbach; A H Sharpe
Journal:  Curr Opin Immunol       Date:  1999-06       Impact factor: 7.486

9.  The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival.

Authors:  T A Judge; Z Wu; X G Zheng; A H Sharpe; M H Sayegh; L A Turka
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

10.  CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T cell blasts.

Authors:  C Olsson; K Riesbeck; M Dohlsten; E Michaëlsson; K Riebeck
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

View more
  30 in total

Review 1.  Use of nonobese diabetic mice to understand human type 1 diabetes.

Authors:  Terri C Thayer; S Brian Wilson; Clayton E Mathews
Journal:  Endocrinol Metab Clin North Am       Date:  2010-07-08       Impact factor: 4.741

2.  The net effect of costimulatory blockers is dependent on the subset and activation status of the autoreactive T cells.

Authors:  Ping Zhang; Deming Sun; Yan Ke; Henry J Kaplan; Hui Shao
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

3.  IFN-gamma-dependent regulatory circuits in immune inflammation highlighted in diabetes.

Authors:  Boris Calderon; Anish Suri; Xiaoou O Pan; Jason C Mills; Emil R Unanue
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

Review 4.  Inhibitory receptor agonists: the future of autoimmune disease therapeutics?

Authors:  Stephanie Grebinoski; Dario Aa Vignali
Journal:  Curr Opin Immunol       Date:  2020-06-30       Impact factor: 7.486

Review 5.  Checkpoint blockade in cancer immunotherapy.

Authors:  Alan J Korman; Karl S Peggs; James P Allison
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

Review 6.  Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

Authors:  Hélène Bour-Jordan; Jonathan H Esensten; Marc Martinez-Llordella; Cristina Penaranda; Melanie Stumpf; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

7.  OX40 costimulation turns off Foxp3+ Tregs.

Authors:  Minh Diem Vu; Xiang Xiao; Wenda Gao; Nicolas Degauque; Ming Chen; Alexander Kroemer; Nigel Killeen; Naoto Ishii; Xian Chang Li
Journal:  Blood       Date:  2007-06-15       Impact factor: 22.113

Review 8.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

9.  Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells.

Authors:  Thomas Enzler; Silke Gillessen; Michael Dougan; James P Allison; Donna Neuberg; Darryl A Oble; Martin Mihm; Glenn Dranoff
Journal:  Blood       Date:  2007-05-04       Impact factor: 22.113

10.  Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Authors:  Brian T Fife; Kristen E Pauken; Todd N Eagar; Takashi Obu; Jenny Wu; Qizhi Tang; Miyuki Azuma; Matthew F Krummel; Jeffrey A Bluestone
Journal:  Nat Immunol       Date:  2009-09-27       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.